Everest Medicines Limited (1952.HK)

HKD 50.8

(3.15%)

Operating Income Summary of Everest Medicines Limited

Everest Medicines Limited's latest annual operating income in 2023 was -932.73 Million CNY , up 33.39% from previous year.
Everest Medicines Limited's latest quarterly operating income in 2024 Q2 was -335.87 Million CNY , down 0.0% from previous quarter.
Everest Medicines Limited reported an annual operating income of -1.4 Billion CNY in 2022, down -33.44% from previous year.
Everest Medicines Limited reported an annual operating income of -1.04 Billion CNY in 2021, down -52.41% from previous year.
Everest Medicines Limited reported a quarterly operating income of -335.87 Million CNY for 2024 Q1, down -48.03% from previous quarter.
Everest Medicines Limited reported a quarterly operating income of -226.9 Million CNY for 2023 Q4, down -7.16% from previous quarter.

Annual Operating Income Chart of Everest Medicines Limited (2023 - 2018)

Historical Annual Operating Income of Everest Medicines Limited (2023 - 2018)

Year	Operating Income	Operating Income Growth
2023	-932.73 Million CNY	33.39%
2022	-1.4 Billion CNY	-33.44%
2021	-1.04 Billion CNY	-52.41%
2020	-688.45 Million CNY	-290.92%
2019	-176.11 Million CNY	-38.47%
2018	-127.18 Million CNY	0.0%

Year	Operating Income	Operating Income Growth
2024 Q2	-335.87 Million CNY	0.0%
2024 Q1	-335.87 Million CNY	-48.03%
2023 Q4	-226.9 Million CNY	-7.16%
2023 Q2	-213.89 Million CNY	0.0%
2023 FY	-932.73 Million CNY	33.39%
2023 Q1	-213.89 Million CNY	46.11%
2023 Q3	-211.73 Million CNY	1.01%
2022 Q3	-396.92 Million CNY	-29.95%
2022 Q4	-396.92 Million CNY	0.0%
2022 Q2	-305.43 Million CNY	0.0%
2022 FY	-1.4 Billion CNY	-33.44%
2022 Q1	-305.43 Million CNY	6.17%
2021 Q3	-325.51 Million CNY	-63.48%
2021 Q2	-199.11 Million CNY	0.0%
2021 FY	-1.04 Billion CNY	-52.41%
2021 Q1	-199.11 Million CNY	4.47%
2021 Q4	-325.51 Million CNY	0.0%
2020 FY	-688.45 Million CNY	-290.92%
2020 Q3	-208.42 Million CNY	-74.03%
2020 Q2	-119.76 Million CNY	-139.32%
2020 Q4	-208.42 Million CNY	0.0%
2020 Q1	304.58 Million CNY	0.0%
2019 FY	-176.11 Million CNY	-38.47%
2019 Q1	99.53 Million CNY	0.0%
2018 FY	-127.18 Million CNY	0.0%

Peer Operating Income Comparison of Everest Medicines Limited

Name	Operating Income	Operating Income Difference
Uni-Bio Science Group Limited	67.76 Million HKD	1476.369%
CK Life Sciences Int'l., (Holdings) Inc.	897.95 Million HKD	203.874%